 |
138 Diseases |  |
93 Trials |
|
93 Trials |  |
2194 News |  |
| «12...22232425262728293031323334» |
- |||||| Erleada (apalutamide) / J&J, Firmagon (degarelix) / Astellas, Ferring
Enrollment open: PRESTO: A Study of Androgen Annihilation in High-Risk Biochemically Relapsed Prostate Cancer (clinicaltrials.gov) - Mar 29, 2017
P3, N=504, Recruiting, Sponsor: Alliance Foundation Trials, LLC.
Not yet recruiting --> Recruiting
- | Erleada (apalutamide) / J&J
New P2 trial: A Study of Docetaxel + ARN-509 in Castration-Resistant Prostate Cancer (clinicaltrials.gov) - Mar 28, 2017
P2, N=33, Not yet recruiting, Sponsor: Dana-Farber Cancer Institute
- |||| Kisqali (ribociclib) / Novartis
Trial primary completion date, Combination therapy, Metastases: CompLEEment-1: Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With HR+ HER2- aBC (clinicaltrials.gov) - Mar 24, 2017
P3, N=3000, Recruiting, Sponsor: Novartis Pharmaceuticals
Not yet recruiting --> Recruiting Trial primary completion date: Nov 2020 --> Nov 2019
- ||||||| NN1213 / Novo Nordisk
Trial completion, Enrollment change, Trial primary completion date: Randomized Trial of Adjuvant Hormonal Therapy in Surgically Treated Prostate Cancer Patients at High Risk for Recurrence (clinicaltrials.gov) - Mar 23, 2017
P3, N=64, Completed, Sponsor: M.D. Anderson Cancer Center
Trial primary completion date: Nov 2020 --> Nov 2019 Active, not recruiting --> Completed | N=496 --> 64 | Trial primary completion date: Jun 2018 --> Mar 2017
- | Enrollment open: A Study of Definitive Therapy to Treat Prostate Cancer After Prostatectomy (clinicaltrials.gov) - Mar 22, 2017
P2, N=33, Recruiting, Sponsor: Sidney Kimmel Comprehensive Cancer Center
Active, not recruiting --> Completed | N=496 --> 64 | Trial primary completion date: Jun 2018 --> Mar 2017 Not yet recruiting --> Recruiting
- |||||||||| Orgovyx (relugolix) / Intas, Gedeon Richter, Takeda, ASKA Pharma, Sumitomo Pharma, Pfizer
New P3 trial, Metastases: HERO: A Study to Evaluate the Safety and Efficacy of Relugolix in Men With Advanced Prostate Cancer (clinicaltrials.gov) - Mar 21, 2017
P3, N=1125, Recruiting, Sponsor: Myovant Sciences GmbH
- | leuprolide acetate for depot suspension / Generic mfg.
New trial: The Relation of GnRH Treatment to QTc Interval in Transgender Females (clinicaltrials.gov) - Mar 12, 2017
P=N/A, N=23, Recruiting, Sponsor: University of California, San Francisco
- || Avastin (bevacizumab) / Roche
Trial primary completion date, Metastases: BOOSTER: Bevacizumab Plus Paclitaxel Optimization Study With Interventional Aintenance Endocrine Therapy in Breast Cancer (clinicaltrials.gov) - Mar 8, 2017
P2, N=160, Active, not recruiting, Sponsor: Japan Breast Cancer Research Group
Not yet recruiting --> Recruiting Trial primary completion date: Jun 2017 --> Jun 2018
- | Emcyt (estramustine) / Pfizer, Nippon Shinyaku
Trial primary completion date: Chemotherapy and Hormone Therapy in Treating Patients With Prostate Cancer (clinicaltrials.gov) - Mar 3, 2017
P2, N=63, Active, not recruiting, Sponsor: University of Massachusetts, Worcester
Trial primary completion date: Jun 2017 --> Jun 2018 Trial primary completion date: Feb 2017 --> Feb 2018
- | Estrace topical (estradiol) / AbbVie, Estrace (estradiol) / AbbVie
Trial completion: Neurophysiology of Postpartum Depression in an Experimental Model of Pregnancy and Parturition (clinicaltrials.gov) - Feb 23, 2017
P=N/A, N=30, Completed, Sponsor: University of North Carolina, Chapel Hill
Trial primary completion date: Feb 2017 --> Feb 2018 Active, not recruiting --> Completed
- ||||| Piqray (alpelisib) / Novartis
New P2 trial, Metastases: BYLieve: Study Assessing the Efficacy and Safety of Alpelisib Plus Fulvestrant or Letrozole, Based on Prior Endocrine Therapy, in Patients With PIK3CA Mutant, HR+, HER2- Advanced Breast Cancer Who Have Progressed on or After Prior Treatments (clinicaltrials.gov) - Feb 16, 2017
P2, N=160, Not yet recruiting, Sponsor: Novartis Pharmaceuticals
- || leuprolide acetate for depot suspension / Generic mfg.
Trial primary completion date: A Study to Assess the Safety and Efficacy of Enantone (Leuprorelin) in Central Precocious Puberty (CPP) Among Chinese Participants (clinicaltrials.gov) - Feb 16, 2017
P=N/A, N=300, Not yet recruiting, Sponsor: Takeda
Active, not recruiting --> Completed Trial primary completion date: Jun 2018 --> Feb 2018
- leuprolide acetate for depot suspension / Generic mfg.
Enrollment closed: Generation of Positive Biological Samples to Leuprolide Acetate for Doping Control (clinicaltrials.gov) - Feb 10, 2017
P1, N=5, Active, not recruiting, Sponsor: Parc de Salut Mar
Trial primary completion date: Jun 2018 --> Feb 2018 Not yet recruiting --> Active, not recruiting
- | leuprolide acetate for depot suspension / Generic mfg.
Biomarker, New P4 trial: Menopausal Sleep Fragmentation and Body Fat Gain (clinicaltrials.gov) - Feb 8, 2017
P4, N=58, Not yet recruiting, Sponsor: Brigham and Women's Hospital
- New P2 trial: A Study of Definitive Therapy to Treat Prostate Cancer After Prostatectomy (clinicaltrials.gov) - Feb 6, 2017
P2, N=33, Not yet recruiting, Sponsor: Sidney Kimmel Comprehensive Cancer Center
- | leuprolide acetate for depot suspension / Generic mfg.
Phase classification: A Study to Assess the Safety and Efficacy of Enantone (Leuprorelin) in Central Precocious Puberty (CPP) Among Chinese Participants (clinicaltrials.gov) - Feb 1, 2017
P=N/A, N=300, Not yet recruiting, Sponsor: Takeda
Not yet recruiting --> Active, not recruiting Phase classification: P4 --> P=N/A
- Keytruda (pembrolizumab) / Merck (MSD), nelitolimod (SD-101) / TriSalus Life Sci, UT MD Anderson Cancer Center
Trial initiation date, Trial primary completion date, PD(L)-1 Biomarker: Pembrolizumab +/- SD-101 in Hormone-Na (clinicaltrials.gov) - Jan 31, 2017
P2, N=60, Not yet recruiting, Sponsor: Lawrence Fong
Phase classification: P4 --> P=N/A Initiation date: Sep 2016 --> Feb 2017 | Trial primary completion date: Sep 2018 --> Feb 2019
- Trial primary completion date, Metastases: LEO: Study of GnRH-A [Leuprorelin(Lorelin Depot] Plus Leterozole +/- Everolimus for Premenopausal Women With Metastatic Breast Cancer (clinicaltrials.gov) - Jan 26, 2017
P2, N=137, Recruiting, Sponsor: Asan Medical Center
Initiation date: Sep 2016 --> Feb 2017 | Trial primary completion date: Sep 2018 --> Feb 2019 Trial primary completion date: Jul 2016 --> Dec 2017
- | leuprolide acetate for depot suspension / Generic mfg.
New P1 trial: Phase 1 Study to Evaluate the Pharmacokinetics and Safety Following SC Administration of DWJ108J in Patients With Prostate Cancer (clinicaltrials.gov) - Jan 24, 2017
P1, N=44, Not yet recruiting, Sponsor: Daewoong Pharmaceutical Co. LTD.
- |||||| Kisqali (ribociclib) / Novartis
Enrollment open, Combination therapy, Metastases: CompLEEment-1: Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With HR+ HER2- aBC (clinicaltrials.gov) - Jan 4, 2017
P3, N=3000, Recruiting, Sponsor: Novartis Pharmaceuticals
Trial primary completion date: Jul 2016 --> Dec 2017 Not yet recruiting --> Recruiting
- |||||||||| Erleada (apalutamide) / J&J, Firmagon (degarelix) / Astellas, Ferring
New P3 trial: PRESTO: A Study of Androgen Annihilation in High-Risk Biochemically Relapsed Prostate Cancer (clinicaltrials.gov) - Jan 3, 2017
P3, N=504, Not yet recruiting, Sponsor: Alliance Foundation Trials, LLC.
- | Keytruda (pembrolizumab) / Merck (MSD), nelitolimod (SD-101) / TriSalus Life Sci, UT MD Anderson Cancer Center
New P2 trial, PD(L)-1 Biomarker: Pembrolizumab +/- SD-101 in Hormone-Na (clinicaltrials.gov) - Jan 3, 2017
P2, N=60, Not yet recruiting, Sponsor: Lawrence Fong
- leuprolide acetate for depot suspension / Generic mfg.
Enrollment closed, Enrollment change: Pilot Study of Leuprolide to Improve Immune Function After Allogeneic Bone Marrow Transplantation (clinicaltrials.gov) - Dec 30, 2016
P2, N=70, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting | N=236 --> 70
- ||||| leuprolide acetate for depot suspension / Generic mfg.
New P4 trial: A Study to Assess the Safety and Efficacy of Enantone (Leuprorelin) in Central Precocious Puberty (CPP) Among Chinese Participants (clinicaltrials.gov) - Dec 15, 2016
P4, N=300, Not yet recruiting, Sponsor: Takeda
- leuprolide acetate for depot suspension / Generic mfg.
Trial initiation date, Trial primary completion date: Treatment of Uterine Fibroids With Magnetic Resonance Guided High Intensity Focused Ultrasound (clinicaltrials.gov) - Dec 14, 2016
P3, N=30, Not yet recruiting, Sponsor: Thunder Bay Regional Research Institute
Recruiting --> Active, not recruiting | N=236 --> 70 Initiation date: Sep 2016 --> Mar 2017 | Trial primary completion date: Sep 2018 --> Mar 2019
- Erleada (apalutamide) / J&J
Enrollment open, Trial initiation date: Apalutamide and Leuprolide in Intermediate and High-risk Prostate Cancer (clinicaltrials.gov) - Dec 13, 2016
P2, N=57, Recruiting, Sponsor: Case Comprehensive Cancer Center
Initiation date: Sep 2016 --> Mar 2017 | Trial primary completion date: Sep 2018 --> Mar 2019 Not yet recruiting --> Recruiting | Initiation date: May 2016 --> Oct 2016
- | Keytruda (pembrolizumab) / Merck (MSD)
New P1/2 trial, Metastases: PEER: Pembrolizumab and Exemestane/ Leuprolide in Premenopausal HR+/ HER2- Locally Advanced or Metastatic Breast Cancer (clinicaltrials.gov) - Dec 13, 2016
P1/2, N=25, Not yet recruiting, Sponsor: National Taiwan University Hospital
- ||||||| leuprolide acetate for depot suspension / Generic mfg.
Trial completion, Trial primary completion date: A Study of the Effect of Enantone LP 11.25 mg (Leuprorelin) on the Histological Progression of Indolent Prostate Cancer (clinicaltrials.gov) - Dec 8, 2016
P3, N=120, Completed, Sponsor: Takeda
Not yet recruiting --> Recruiting | Initiation date: May 2016 --> Oct 2016 Active, not recruiting --> Completed | Trial primary completion date: Jul 2016 --> Nov 2016
- Xtandi (enzalutamide capsule) / Pfizer, Astellas
Trial primary completion date, Metastases: LHRH Analogue Therapy With Enzalutamide or Bicalutamide in Treating Patients With Hormone Sensitive Prostate Cancer (clinicaltrials.gov) - Dec 6, 2016
P2, N=92, Recruiting, Sponsor: Barbara Ann Karmanos Cancer Institute
Active, not recruiting --> Completed | Trial primary completion date: Jul 2016 --> Nov 2016 Trial primary completion date: Dec 2016 --> Mar 2017
- cabazitaxel / Generic mfg.
Enrollment open: ACDC-RP: Anti-Androgens and Cabazitaxel in Defining Complete Response in Prostatectomy (ACDC Trial) (clinicaltrials.gov) - Dec 2, 2016
P2, N=76, Recruiting, Sponsor: University Health Network, Toronto
Trial primary completion date: Dec 2016 --> Mar 2017 Not yet recruiting --> Recruiting
- || New P3 trial: Neoadjuvant Chemo-endocrine Therapy Versus Chemotherapy Alone in ER-positive, HER2-negative Breast Cancer (clinicaltrials.gov) - Dec 2, 2016
P3, N=213, Active, not recruiting, Sponsor: Fudan University
- Ibrance (palbociclib) / Pfizer
Enrollment open, Trial initiation date, Combination therapy, Metastases: Young-PEARL: A Study of Palbociclib With Exemestane Plus GnRH Versus Capecitabine in Premenopausal Women With HR+ MBC (clinicaltrials.gov) - Dec 1, 2016
P2, N=122, Recruiting, Sponsor: Samsung Medical Center
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting | Initiation date: Nov 2015 --> Jun 2016
- ||||| leuprolide acetate for depot suspension / Generic mfg., zoledronic acid / Generic mfg.
Trial initiation date: TROG 03.04 - RADAR: RADAR Trial - Randomised Androgen Deprivation and Radiotherapy (clinicaltrials.gov) - Nov 21, 2016
P3, N=1000, Active, not recruiting, Sponsor: Trans-Tasman Radiation Oncology Group (TROG)
Not yet recruiting --> Recruiting | Initiation date: Nov 2015 --> Jun 2016 Initiation date: Oct 2004 --> Oct 2003
- ||||| Orgovyx (relugolix) / Intas, Gedeon Richter, Takeda, ASKA Pharma, Sumitomo Pharma, Pfizer
Enrollment closed: A Phase 3 Study to Evaluate the Efficacy and Safety of Relugolix (TAK-385) 40 mg Compared With Leuprorelin in the Treatment of Uterine Fibroids (clinicaltrials.gov) - Nov 15, 2016
P3, N=288, Active, not recruiting, Sponsor: Takeda
Initiation date: Oct 2004 --> Oct 2003 Recruiting --> Active, not recruiting
- |||| anastrozole/levonorgestrel (BAY 98-7196) / Bayer
Trial completion: Bay98-7196, Dose Finding / POC Study (clinicaltrials.gov) - Nov 3, 2016
P2b, N=305, Completed, Sponsor: Bayer
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- Menopur (menotropin) / Ferring, Orgalutran (ganirelix acetate) / Organon, Follistim AQ Cartridge (follitropin beta) / Organon
Trial primary completion date: Efficacy of Recombinant FSH/GnRH Antagonist Protocol With and Without LH Adjunct for Egg Bank Donation (clinicaltrials.gov) - Nov 1, 2016
P4, N=50, Recruiting, Sponsor: Michigan Reproductive Medicine
Active, not recruiting --> Completed Trial primary completion date: Apr 2016 --> Apr 2018
- |||||||||| Kisqali (ribociclib) / Novartis
New P3 trial, Combination therapy, Metastases: CompLEEment-1: Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With HR+ HER2- aBC (clinicaltrials.gov) - Oct 20, 2016
P3, N=3000, Not yet recruiting, Sponsor: Novartis Pharmaceuticals
- Yervoy (ipilimumab) / BMS
Trial primary completion date: Ipilimumab + Androgen Depravation Therapy in Prostate Cancer (clinicaltrials.gov) - Oct 19, 2016
P2, N=48, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
Trial primary completion date: Apr 2016 --> Apr 2018 Trial primary completion date: Jun 2017 --> Jun 2018
- Herceptin (trastuzumab) / Roche, trastuzumab/pertuzumab (EG13084) / EirGenix, Perjeta (pertuzumab) / Roche
Enrollment open: NEOADAPT: NEOADjuvant Aromatase Inhibitor and Pertuzumab/Trastuzumab for Women With Breast Cancer (clinicaltrials.gov) - Oct 14, 2016
P2, N=32, Recruiting, Sponsor: Midwestern Regional Medical Center
Trial primary completion date: Jun 2017 --> Jun 2018 Active, not recruiting --> Recruiting
- leuprolide acetate for depot suspension / Generic mfg.
New trial: Brown Adipose Tissue Activity in Pre- and Postmenopausal Women (clinicaltrials.gov) - Oct 7, 2016
P=N/A, N=72, Not yet recruiting, Sponsor: University of Colorado, Denver
- leuprolide acetate for depot suspension / Generic mfg.
Trial completion, Enrollment change: Effects of Estrogen Deficiency on Energy Expenditure (clinicaltrials.gov) - Oct 5, 2016
P=N/A, N=6, Completed, Sponsor: University of Colorado, Denver
Active, not recruiting --> Recruiting Active, not recruiting --> Completed | N=12 --> 6
- progesterone / Generic mfg., leuprolide acetate for depot suspension / Generic mfg., estradiol valerate / Generic mfg.
Trial primary completion date: Endometrial Receptivity Profile in Patients With Endometrial Proliferation Defects (clinicaltrials.gov) - Oct 4, 2016
P=N/A, N=20, Enrolling by invitation, Sponsor: Reproductive Medicine Associates of New Jersey
Active, not recruiting --> Completed | N=12 --> 6 Trial primary completion date: Dec 2015 --> Dec 2017
- leuprolide acetate for depot suspension / Generic mfg., bicalutamide / Generic mfg., docetaxel / Generic mfg.
Enrollment open, Metastases: oligo-mets: A Study of Definitive Therapy to Treat Prostate Cancer (clinicaltrials.gov) - Oct 3, 2016
P2, N=33, Recruiting, Sponsor: Sidney Kimmel Comprehensive Cancer Center
Trial primary completion date: Dec 2015 --> Dec 2017 Not yet recruiting --> Recruiting
- leuprolide acetate for depot suspension / Generic mfg.
New P1 trial: Generation of Positive Biological Samples to Leuprolide Acetate for Doping Control (clinicaltrials.gov) - Sep 29, 2016
P1, N=8, Not yet recruiting, Sponsor: Parc de Salut Mar
- Suprefact (buserelin acetate) / Sanofi, Firmagon (degarelix) / Astellas, Ferring
Trial primary completion date: Radiation Therapy With or Without Androgen-Deprivation Therapy in Treating Patients With Prostate Cancer (clinicaltrials.gov) - Sep 29, 2016
P3, N=1538, Active, not recruiting, Sponsor: Radiation Therapy Oncology Group
Not yet recruiting --> Recruiting Trial primary completion date: Dec 2020 --> May 2022
- | tamoxifen / Generic mfg.
New P2 trial: ASPAIT: Adjuvant Ovarian Suppression Plus Aromatase Inhibitor or Tamoxifen in Young Women (clinicaltrials.gov) - Sep 26, 2016
P2, N=688, Recruiting, Sponsor: First Affiliated Hospital, Sun Yat-Sen University
- ||| leuprolide acetate for depot suspension / Generic mfg.
Trial completion: Real Life Evaluation of Lupron in the Management of Prostate Cancer: A Canadian Post Marketing Observational Study (clinicaltrials.gov) - Sep 23, 2016
P=N/A, N=553, Completed, Sponsor: AbbVie (prior sponsor, Abbott)
Trial primary completion date: Dec 2020 --> May 2022 Active, not recruiting --> Completed
- || sunitinib / Generic mfg.
Trial primary completion date: Sunitinib Malate With Hormonal Ablation for Patients Who Will Have Prostatectomy (clinicaltrials.gov) - Sep 15, 2016
P2, N=64, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
Active, not recruiting --> Completed Trial primary completion date: Dec 2017 --> Dec 2018
- leuprolide acetate for depot suspension / Generic mfg.
Trial primary completion date: Pilot Study of Leuprolide to Improve Immune Function After Allogeneic Bone Marrow Transplantation (clinicaltrials.gov) - Sep 2, 2016
P2, N=236, Recruiting, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: Dec 2017 --> Dec 2018 Trial primary completion date: Apr 2017 --> Dec 2017
- || letrozole / Generic mfg., leuprolide acetate for depot suspension / Generic mfg., everolimus / Generic mfg.
Trial primary completion date: Study of (1) Everolimus, (2) Estrogen Deprivation Therapy (EDT) With Leuprolide + Letrozole and (3) Everolimus + EDT in Patients With Unresectable Fibrolamellar Hepatocellular Carcinoma (FLL-HCC) (clinicaltrials.gov) - Aug 16, 2016
P2, N=84, Active, not recruiting, Sponsor: Memorial Sloan Kettering Cancer Center
Trial primary completion date: Apr 2017 --> Dec 2017 Trial primary completion date: Jul 2016 --> Jul 2017